Cargando…
Erythrodermic Psoriasis Managed with Risankizumab
Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies. EP is usually a therapeutic challenge, where topical and conventi...
Autores principales: | Alajlan, Abdulmajeed, Madani, Abdulaziz, Qadoumi, Tala Ammar, Aljaloud, Alhanouf, Alessa, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459644/ https://www.ncbi.nlm.nih.gov/pubmed/36158862 http://dx.doi.org/10.1159/000525774 |
Ejemplares similares
-
Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021) -
A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022) -
The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
por: Rao, Suman, et al.
Publicado: (2020) -
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019) -
Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)